Tectonic Therapeutic (TECX) Income towards Parent Company (2017 - 2026)
Tectonic Therapeutic (TECX) reported Income towards Parent Company of -$25.1 million for Q1 2026, down 58.3% year-over-year from -$60.3 million in Q1 2025, and down 146.6% quarter-over-quarter from $53.9 million in Q4 2025.
Tectonic Therapeutic (TECX) Income towards Parent Company (2017 - 2026) Analysis & Trends
Tectonic Therapeutic (TECX) has 10 years of Income towards Parent Company data on file, last reported at -$25.1 million in Q1 2026.
- Income towards Parent Company for Q1 2026 came in at -$25.1 million, down 58.3% year-over-year; the trailing twelve-month figure through Mar 2026 was -$10.2 million (up 81.79% YoY), and the FY2025 annual result was -$1.0 million, up 98.2% from the prior year.
- Income towards Parent Company retreated to -$25.1 million in Q1 2026 per TECX's latest filing, from $53.9 million in the prior quarter.
- Over five years, Income towards Parent Company peaked at $53.9 million in Q4 2025 and troughed at -$29.8 million in Q1 2022.
- A 5-year average of -$14.1 million and a median of -$17.7 million in 2024 frame the typical range for Income towards Parent Company.
- The sharpest annual moves came in 2024 and 2025: Income towards Parent Company sank 76.24% in 2024, then surged 646.12% in 2025.
- A 5-year view of Income towards Parent Company shows it stood at -$25.0 million in 2022, then jumped by 62.92% to -$9.3 million in 2023, then slipped by 6.46% to -$9.9 million in 2024, then surged by 646.12% to $53.9 million in 2025, then sank by 146.6% to -$25.1 million in 2026.
- Business Quant data shows TECX's Income towards Parent Company at -$25.1 million in Q1 2026, $53.9 million in Q4 2025, and -$19.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Tectonic Therapeutic | 528.16 Mn | 291.27 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -25.13 Mn |
| Dec 31, 2025 | 53.92 Mn |
| Sep 30, 2025 | -19.04 Mn |
| Jun 30, 2025 | -19.98 Mn |
| Mar 31, 2025 | -15.87 Mn |
| Dec 31, 2024 | -9.87 Mn |
| Sep 30, 2024 | -17.72 Mn |
| Jun 30, 2024 | -12.67 Mn |
| Mar 31, 2024 | -12.74 Mn |
| Dec 31, 2023 | -9.28 Mn |
| Sep 30, 2023 | -10.05 Mn |
| Jun 30, 2023 | -10.45 Mn |
| Mar 31, 2023 | -24.97 Mn |
| Dec 31, 2022 | -25.01 Mn |
| Sep 30, 2022 | -22.87 Mn |
| Jun 30, 2022 | -28.06 Mn |
| Mar 31, 2022 | -29.83 Mn |
| Dec 31, 2021 | -28.21 Mn |
| Sep 30, 2021 | -32.62 Mn |
| Jun 30, 2021 | -31.39 Mn |